Learn More
BACKGROUND Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters. Cyclophosphamide is a prodrug that requires oxidation to 4-hydroxycyclophosphamide, which yields a cytotoxic alkylating agent. The initial oxidation is catalysed by cytochrome P450(More)
OBJECTIVE A SNP in the NQO1 gene has been implicated in the response of patients with breast cancer to anthracycline containing regimens. NQO1, and its homologue NQO2, share many substrates yet retain distinct functional differences, with NQO2 being a more permissive molecule for electron accepting substrates. We aimed to determine whether functional NQO2(More)
The purpose of this study was to identify risk factors for urinary retention (UR) in frail, elderly patients, to determine its prevalence, and to assess the validity of the use of the BladderScan BVI 2500+ ultrasound scanner to measure postvoid residual urine volumes of > or = 150 ml. Probable UR was defined as two consecutive ultrasound scans with postvoid(More)
Double-blind and long-term open-label studies have demonstrated a remarkably favorable safety profile for bevantolol. The drug was associated with a low incidence of adverse experiences similar to that observed with placebo. The adverse experiences were mostly mild to moderate and of the types found previously for other beta-blocking drugs. Very few(More)
Rats immune to one of 6 syngeneic tumours with individually distinct tumour associated rejection antigens, or rats bearing growing tumours were tested for cell mediated immunity to their own or other tumours in comparison with normal control rats using a microcytotoxicity assay. Lymph node cells (LNC) were tested at ratios of 2000, 1000, 500 and 250 per(More)
  • 1